Michael Davidson, MD

  • 17Articles
  • 46.4KReads
  • 2001–2022Active
  • 60Collaborators
  • 164Citations

About

Michael Davidson, MD, is affiliated with Nicosia University School of Medicine in Cyprus and has published extensively from 2001 to 2022. His work focuses on metabolic disorders and their relationship with psychiatric conditions such as schizophrenia and schizoaffective disorders, including studies on antipsychotic-induced weight gain and metabolic side effects. He has also contributed research on neurology, dementia, child and adolescent psychiatry, and the clinical management of related behavioral symptoms. His publications include randomized controlled trials investigating pharmacological treatments and metabolic risk factors in psychiatric populations.

Publications

JCP
Add-on Pramipexole for Schizophrenia
Original Research

Add-on Pramipexole for Schizophrenia

August 1, 2022

Several small clinical trials have reported that the dopamine agonist pramipexole was beneficial in treating patients with schizophrenia. This 16-week, multicenter, double-blind, randomized, placebo-controlled study was conducted to test...
, , , et al
JCP
Original Research

MIN-101 and Cognition in Schizophrenia Patients

May 15, 2018

The currently available dopamine-blocking antipsychotics haven' t been of much help with cognitive deficits in schizophrenia. This post hoc analysis of an RCT examines whether MIN-101, which combines sigma-2...
, , , et al
JCP
Original Research

BL-1020, a New γ-Aminobutyric Acid-Enhanced Antipsychotic: Results of 6-Week, Randomized, Double-Blind, Controlled, Efficacy and Safety Study

September 15, 2012

, , , et al
JCP
Original Research

A Multicenter, Add-On Randomized Controlled Trial of Low-Dose d-Serine for Negative and Cognitive Symptoms of Schizophrenia

June 15, 2012

, , , et al
JCP
Original Research

Body Mass Index and Future Schizophrenia in Israeli Male Adolescents

November 1, 2004

, , , et al
JCP
Original Research

Behavioral and Psychological Symptoms in Patients With Dementia as a Target for Pharmacotherapy With Risperidone

October 15, 2004

, , , et al
JCP
Article

Antipsychotic Drugs, Insulin Resistance, Hyperglycemia, and Diabetes Mellitus

May 1, 2004

, , , et al
JCP
Article

Conclusions: Antipsychotic-Induced Weight Gain and Metabolic Abnormalities

May 1, 2004

, , , et al
JCP
Article

Epidemiology of Cardiovascular Disease and Major Metabolic Risk Factors

May 1, 2004

, , , et al
JCP
Article

The Impact of Atypical Antipsychotics on Weight Gain

May 1, 2004

, , , et al
JCP
Article

Monitoring Metabolic Side Effects

May 1, 2004

, , , et al
JCP
Article

Treatment Recommendations for Psychiatrists

May 1, 2004

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe